A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Walker, Brian A. (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn) , Raab, Marc-Steffen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2019
In: Leukemia
Year: 2018, Jahrgang: 33, Heft: 1, Pages: 159-170
ISSN:1476-5551
DOI:10.1038/s41375-018-0196-8
Online-Zugang:Verlag, Volltext: https://doi.org/10.1038/s41375-018-0196-8
Verlag, Volltext: https://www.nature.com/articles/s41375-018-0196-8
Volltext
Verfasserangaben:Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell, T. Cody Ashby, Michael Bauer, Faith Davies, Adam Rosenthal, Hongwei Wang, Pingping Qu, Antje Hoering, Mehmet Samur, Fadi Towfic, Maria Ortiz, Erin Flynt, Zhinuan Yu, Zhihong Yang, Dan Rozelle, John Obenauer, Matthew Trotter, Daniel Auclair, Jonathan Keats, Niccolo Bolli, Mariateresa Fulciniti, Raphael Szalat, Phillipe Moreau, Brian Durie, A. Keith Stewart, Hartmut Goldschmidt, Marc S. Raab, Hermann Einsele, Pieter Sonneveld, Jesus San Miguel, Sagar Lonial, Graham H. Jackson, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth Morgan

MARC

LEADER 00000caa a2200000 c 4500
001 1670146464
003 DE-627
005 20240323101244.0
007 cr uuu---uuuuu
008 190726r20192018xx |||||o 00| ||eng c
024 7 |a 10.1038/s41375-018-0196-8  |2 doi 
035 |a (DE-627)1670146464 
035 |a (DE-599)KXP1670146464 
035 |a (OCoLC)1341234791 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Walker, Brian A.  |e VerfasserIn  |0 (DE-588)1184512817  |0 (DE-627)1663621322  |4 aut 
245 1 0 |a A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis  |c Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell, T. Cody Ashby, Michael Bauer, Faith Davies, Adam Rosenthal, Hongwei Wang, Pingping Qu, Antje Hoering, Mehmet Samur, Fadi Towfic, Maria Ortiz, Erin Flynt, Zhinuan Yu, Zhihong Yang, Dan Rozelle, John Obenauer, Matthew Trotter, Daniel Auclair, Jonathan Keats, Niccolo Bolli, Mariateresa Fulciniti, Raphael Szalat, Phillipe Moreau, Brian Durie, A. Keith Stewart, Hartmut Goldschmidt, Marc S. Raab, Hermann Einsele, Pieter Sonneveld, Jesus San Miguel, Sagar Lonial, Graham H. Jackson, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth Morgan 
264 1 |c 2019 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online: 2 July 2018 
500 |a Gesehen am 26.07.2019 
520 |a Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches. 
534 |c 2018 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
700 1 |a Raab, Marc-Steffen  |d 1973-  |e VerfasserIn  |0 (DE-588)124052460  |0 (DE-627)706520998  |0 (DE-576)293998027  |4 aut 
773 0 8 |i Enthalten in  |t Leukemia  |d London : Springer Nature, 1997  |g 33(2019), 1, Seite 159-170  |h Online-Ressource  |w (DE-627)32046699X  |w (DE-600)2008023-2  |w (DE-576)094139733  |x 1476-5551  |7 nnas  |a A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis 
773 1 8 |g volume:33  |g year:2019  |g number:1  |g pages:159-170  |g extent:12  |a A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis 
856 4 0 |u https://doi.org/10.1038/s41375-018-0196-8  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.nature.com/articles/s41375-018-0196-8  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190726 
993 |a Article 
994 |a 2019 
998 |g 124052460  |a Raab, Marc-Steffen  |m 124052460:Raab, Marc-Steffen  |d 910000  |d 910100  |e 910000PR124052460  |e 910100PR124052460  |k 0/910000/  |k 1/910000/910100/  |p 29 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |e 910000PG102258023X  |e 910100PG102258023X  |k 0/910000/  |k 1/910000/910100/  |p 28 
999 |a KXP-PPN1670146464  |e 3497690546 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"doi":["10.1038/s41375-018-0196-8"],"eki":["1670146464"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"12 S."}],"relHost":[{"origin":[{"publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"part":{"issue":"1","pages":"159-170","year":"2019","text":"33(2019), 1, Seite 159-170","volume":"33","extent":"12"},"note":["Gesehen am 15.03.04"],"language":["eng"],"recId":"32046699X","disp":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisLeukemia","pubHistory":["Nachgewiesen 11.1997 -"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia","title":"Leukemia"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"zdb":["2008023-2"],"eki":["32046699X"],"issn":["1476-5551"]}}],"title":[{"title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","title_sort":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis"}],"person":[{"family":"Walker","display":"Walker, Brian A.","role":"aut","given":"Brian A."},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","given":"Hartmut","role":"aut"},{"role":"aut","given":"Marc-Steffen","family":"Raab","display":"Raab, Marc-Steffen"}],"name":{"displayForm":["Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell, T. Cody Ashby, Michael Bauer, Faith Davies, Adam Rosenthal, Hongwei Wang, Pingping Qu, Antje Hoering, Mehmet Samur, Fadi Towfic, Maria Ortiz, Erin Flynt, Zhinuan Yu, Zhihong Yang, Dan Rozelle, John Obenauer, Matthew Trotter, Daniel Auclair, Jonathan Keats, Niccolo Bolli, Mariateresa Fulciniti, Raphael Szalat, Phillipe Moreau, Brian Durie, A. Keith Stewart, Hartmut Goldschmidt, Marc S. Raab, Hermann Einsele, Pieter Sonneveld, Jesus San Miguel, Sagar Lonial, Graham H. Jackson, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth Morgan"]},"recId":"1670146464","note":["Published online: 2 July 2018","Gesehen am 26.07.2019"],"language":["eng"],"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}]} 
SRT |a WALKERBRIAAHIGHRISKD2019